Silence Therapeutics Releases Late-Breaking Phase 2 Zerlasiran Data
DAIC
NOVEMBER 18, 2024
Nissen, MD, Chief Academic Officer of the Heart, Vascular and Thoracic Institute at Cleveland Clinic and the study’s lead author. This is a genetic risk factor that we’ve been unable to treat and I’m excited about the potential for gene-silencing approaches to help these patients.”
Let's personalize your content